Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsOscar Health Benlysta Prior Auth Policy | OpenPaye…
    Ask Trek AI about this page
    CurrentOscar HealthPolicy PG014

    Benlysta (belimumab) Coverage and Prior Authorization

    Customize your policy alerts

    Sign up for Oscar Health Policy PG014 alerts

    Get alerted when Policy PG014 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical necessity and prior authorization criteria for intravenous and subcutaneous Benlysta (belimumab) in members aged 5 years and older with active systemic lupus erythematosus or active lupus nephritis receiving standard therapy.

    Policy Summary
    PayerOscar Health
    PolicyBenlysta (belimumab) Coverage and Prior Authorization
    Policy CodePolicy PG014
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewDec 1, 202613d
    Next Review DateN/A
    Key ActionPrior authorization is required, and the member must meet the applicable general and indication-specific criteria.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    2Covered indications
    5 yearsMinimum member age
    4 pens/28 daysQuantity limit
    Up to 12 monthsApproval period
    2Administration forms

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    General Coverage Criteria

    General Medical Necessity Criteria

    Covered when ALL of the following general medical necessity criteria are met.

    General medical necessity

    • Age: The member is 5 years of age or older.>=5 years
    • Safety exclusion: There is no evidence of severe active central nervous system lupus, including altered mental function or confusion, vision problems, or seizures.
    • Dosing and quantity: Benlysta is prescribed at a dose and frequency within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication, and use is within the Plan's quantity limit.4 pens every 28 days
    • Clinical review: The member meets the applicable initial clinical review or subsequent clinical review criteria.

    Initial Therapy - Active Systemic Lupus Erythematosus

    Covered for initial therapy when ALL of the following are met.

    Initial active SLE therapy

    • General criteria: The member meets the general medical necessity criteria.
    • Prescriber: The medication is prescribed by a rheumatologist.
    • SLE diagnostic support: Before initiating therapy, positive autoantibodies relevant to systemic lupus erythematosus are documented.ANA by IFA >=1:80; anti-dsDNA; anti-Smith; antiphospholipid antibodies; or low complement proteins
    • Standard therapy: The member is receiving at least one standard therapy, alone or in combination: an antimalarial, corticosteroid, or immunosuppressive.

    Initial Therapy - Active Lupus Nephritis

    Covered for initial therapy when ALL of the following are met.

    Initial active lupus nephritis therapy

    • General criteria: The member meets the general medical necessity criteria.
    • Prescriber: The medication is prescribed by a rheumatologist or nephrologist.
    • Lupus nephritis diagnostic support: Active lupus nephritis is confirmed by kidney biopsy or, before initiating therapy, supported by positive autoantibodies relevant to systemic lupus erythematosus.ANA by IFA >=1:80 or other listed SLE-relevant autoantibody evidence
    • Standard therapy:

    Continuation Therapy - Active SLE or Active Lupus Nephritis

    Covered for continuation therapy when ALL of the following are met.

    Subsequent clinical review

    • Prior criteria: The member continues to meet the applicable general medical necessity and initial clinical review criteria.
    • Treatment response or stability: Recent chart documentation demonstrates either clinical improvement or disease stability since starting Benlysta.Documentation within the last 6 months

      Clinical improvement may include sustained improvement in disease activity or reductions in disease flares. Disease stability may include complete remission, low disease activity, or no new lupus disease activity compared with the previous assessment.

    Coverage excludes members with severe active central nervous system lupus, including manifestations such as altered mental function or confusion, vision problems, or seizures.

    Benlysta must not be used concurrently with other biologic therapies. For active systemic lupus erythematosus, concurrent use with intravenous cyclophosphamide is also excluded.

    Benlysta is considered experimental, investigational, or unproven when used for indications other than active systemic lupus erythematosus or active lupus nephritis receiving standard therapy. Non-covered uses include, among others, ANCA-associated vasculitis or granulomatosis with polyangiitis, antiphospholipid syndrome, COPD or emphysema, cryoglobulinemia, discoid lupus, graft-versus-host disease, idiopathic CD4 lymphocytopenia, idiopathic inflammatory myopathy, immune thrombocytopenia outside SLE, IgG4-related sclerosing disease outside SLE, myasthenia gravis, neuromyelitis optica spectrum disorders, relapsed chronic lymphocytic leukemia, rheumatoid arthritis, Sjögren syndrome, and vasculitis outside SLE.

    Initial Therapy by Indication

    Active Systemic Lupus Erythematosus

    Initial active SLE therapy is covered when ALL criteria are met.

    Active SLE initial therapy

    • Prescriber: The medication is prescribed by a rheumatologist.
    • Diagnostic evidence: Before initiating therapy, positive autoantibodies relevant to systemic lupus erythematosus are documented.ANA by IFA >=1:80; anti-dsDNA; anti-Smith; antiphospholipid antibodies; or low complement proteins
    • Standard therapy: The member is receiving at least one antimalarial, corticosteroid, or immunosuppressive, alone or in combination.

    Continuation and Reauthorization

    Subsequent Clinical Review

    Continuation is covered when ALL of the following are met.

    Continuation criteria

    • Prior criteria: The member continues to meet the applicable general medical necessity and initial clinical review criteria.
    • Improvement or stability: Recent chart documentation shows clinical improvement or disease stability since starting Benlysta.Within the last 6 months

      Improvement includes sustained improvement in disease activity or reductions in disease flares. Stability includes complete remission, low disease activity, or no new lupus disease activity compared with the previous assessment.

    Reauthorization approval period

    When the reauthorization criteria are met:

    Required Standard Therapy

    StepIndicationRequired standard therapy
    1Active systemic lupus erythematosus (SLE)At least one antimalarial, corticosteroid, or immunosuppressive, used alone or in combination
    StepIndicationRequired standard therapy
    1Active lupus nephritisAt least one antimalarial, calcineurin inhibitor, corticosteroid, or immunosuppressive, used alone or in combination

    Covered Codes and Operational Limits

    CPT/HCPCS codes considered medically necessary if criteria are metHCPCSCovered
    J0490Benlysta IV Injection, belimumab, 10 mg
    J3590Benlysta SC (belimumab) Unclassified biologics
    Systemic Lupus Erythematosus diagnosis codesICD-10Covered
    M32.0Drug-induced systemic lupus erythematosus
    M32.10Systemic lupus erythematosus, organ or system involvement unspecified
    M32.11Endocarditis in systemic lupus erythematosus
    M32.12Pericarditis in systemic lupus erythematosus
    M32.13Lung involvement in systemic lupus erythematosus
    M32.15Tubulo-interstitial nephropathy in systemic lupus erythematosus
    M32.19Other organ or system involvement in systemic lupus erythematosus
    M32.8Other forms of systemic lupus erythematosus
    M32.9Systemic lupus erythematosus, unspecified
    Lupus Nephritis diagnosis codesICD-10Covered
    M32.14Glomerular disease in systemic lupus erythematosus
    Quantity Limit
    Quantity limit4 pens
    IntervalEvery 28 days
    Applies toBenlysta (belimumab)
    ANA by IFA
    TestAntinuclear antibody (ANA) by indirect immunofluorescence assay (IFA)
    Required threshold1:80 or higher
    Timing

    Authorization and Documentation Requirements

    Prior Authorization

    Specialist Prior Authorization Required

    Prior authorization is required for Benlysta (belimumab). The request must satisfy the Plan’s general medical-necessity criteria and the applicable indication-specific criteria for active systemic lupus erythematosus (SLE) or active lupus nephritis receiving standard therapy.

    • For active SLE, the medication must be prescribed by a rheumatologist.
    • For active lupus nephritis, the medication must be prescribed by a rheumatologist or nephrologist.
    Prior Authorization

    Reauthorization Required

    Reauthorization is required for continued treatment. When the reauthorization criteria are met, Benlysta may be approved for up to 12 months.

    • Submit the applicable initial-review criteria and recent continuation documentation with each renewal request.

    Clinical Background

    Systemic lupus erythematosus is an autoimmune disease that can affect multiple organs and typically follows a pattern of remission and relapse. Lupus nephritis is kidney inflammation associated with SLE; when active lesions are present, treatment may require immunosuppressive therapy. Belimumab is used with standard therapy for active SLE or active lupus nephritis in members aged 5 years and older.

    Policy Definitions

    Anti-JCV Antibodies
    DefinitionMarkers of exposure to the John Cunningham (JC) virus
    Risk associationPresence is associated with a higher risk of progressive multifocal leukoencephalopathy (PML)
    PML descriptionAn opportunistic viral infection of the brain that can result in severe disability or death
    Antimalarial
    DefinitionA drug class used to treat malaria
    Autoimmune useAlso used in autoimmune diseases
    Examples of conditions

    Benlysta Quantity Limit

    Benlysta (Belimumab) Quantity Limit
    ProductBenlysta (belimumab)
    Quantity limit4 pens
    Limit periodEvery 28 days
    Policy Summary
    PayerOscar Health
    PolicyBenlysta (belimumab) Coverage and Prior Authorization
    Policy CodePolicy PG014
    Change TypeNo material clinical or coverage changes
    Effective DateN/A
    Last ReviewDec 1, 202613d
    Next Review DateN/A
    Key ActionPrior authorization is required, and the member must meet the applicable general and indication-specific criteria.
    SourceLink
    On This Page
    General Coverage CriteriaInitial Therapy by IndicationContinuation and ReauthorizationRequired Standard TherapyCovered Codes and Operational LimitsAuthorization and Documentation RequirementsClinical BackgroundPolicy DefinitionsBenlysta Quantity Limit

    Examples include hydroxychloroquine; prednisone, methylprednisolone, or dexamethasone; and azathioprine, methotrexate, mycophenolate, cyclosporine, or cyclophosphamide.

  1. Combination exclusions: There is no evidence that Benlysta is being used with another biologic therapy or intravenous cyclophosphamide.
  2. The member is receiving at least one standard therapy, alone or in combination: an antimalarial, calcineurin inhibitor, corticosteroid, or immunosuppressive.

    Examples include hydroxychloroquine; cyclosporine or tacrolimus; prednisone, methylprednisolone, or dexamethasone; and azathioprine, cyclophosphamide, or mycophenolate.

  3. Combination exclusion: There is no evidence that Benlysta is being used with another biologic therapy.
  4. Combination exclusions: There is no evidence of concurrent use of Benlysta with another biologic therapy or intravenous cyclophosphamide.
  5. General criteria: The member meets all general medical necessity criteria.
  6. Active Lupus Nephritis

    Initial active lupus nephritis therapy is covered when ALL criteria are met.

    Active lupus nephritis initial therapy

    • Prescriber: The medication is prescribed by a rheumatologist or nephrologist.
    • Diagnostic evidence: Active lupus nephritis is confirmed by kidney biopsy or, before initiating therapy, supported by positive autoantibodies relevant to systemic lupus erythematosus.
    • Standard therapy: The member is receiving at least one antimalarial, calcineurin inhibitor, corticosteroid, or immunosuppressive, alone or in combination.
    • Combination exclusion: There is no evidence of concurrent use of Benlysta with another biologic therapy.
    • General criteria: The member meets all general medical necessity criteria.

    Reauthorization approval

    • The applicable reauthorization criteria are met for the requested product.
    • Approval may be issued for up to 12 months.Up to 12 months
    Positive SLE-relevant autoantibodies must be documented prior to initiating therapy
    Continuation Documentation Timing
    Documentation periodWithin the last 6 months
    Required forContinuation or subsequent clinical review
    Documentation must showClinical improvement or disease stability since starting Benlysta
    Documentation Required

    Clinical and Treatment Documentation

    Submit sufficient clinical and treatment documentation to support the diagnosis, medical necessity, and prior or current therapy. Documentation may include up-to-date chart notes, relevant laboratory results, imaging reports, and records supporting trials of formulary alternatives.

    • Provide chart notes and relevant test results and/or imaging reports supporting the diagnosis.
    • For prior formulary-alternative trials, provide prescription claims records and/or prescription receipts.
    • Document the applicable standard therapy and the requested Benlysta dose and frequency.
    Documentation Required

    SLE Diagnostic Evidence

    For active SLE, submit evidence that the diagnosis is supported by SLE-relevant autoantibodies obtained before therapy initiation.

    • Examples include ANA by IFA at 1:80 or higher, anti-double-stranded DNA, anti-Smith, antiphospholipid antibodies such as anti-RNP, anti-Ro, anti-La, or anti-cardiolipin, and low complement proteins.
    Documentation Required

    Lupus Nephritis Diagnostic Evidence

    For active lupus nephritis, submit documentation supporting the diagnosis through one of the accepted pathways.

    • Kidney biopsy confirming lupus nephritis; or
    • SLE-relevant autoantibodies documented before therapy initiation, such as ANA by IFA at 1:80 or higher, anti-double-stranded DNA, anti-Smith, antiphospholipid antibodies, or low complement proteins.
    Documentation Required

    Renewal Response Documentation

    For continuation requests, recent chart documentation from within the last 6 months must demonstrate that the member has responded to Benlysta or remains clinically stable since starting treatment.

    • Document clinical improvement, such as sustained improvement in disease activity or reductions in disease flares; or
    • Document disease stability, such as complete remission, low disease activity, or no new lupus disease activity compared with the previous assessment.
    Denial Risk

    Failure to Meet Criteria May Result in Denial

    A request may be denied when any general or indication-specific medical-necessity criterion is not met. Confirm eligibility, diagnosis, prescriber, dosing, frequency, quantity, and required treatment conditions before submission.

    • Member must be at least 5 years of age.
    • There must be no evidence of severe active central nervous system lupus, including altered mental function or confusion, vision problems, or seizures.
    • Dose and frequency must be within FDA-approved labeling or supported by compendia or evidence-based published dosing guidelines for the requested indication.
    • The request must remain within the quantity limit of 4 pens every 28 days.
    • The member must meet the applicable initial or subsequent indication-specific criteria, including the required prescriber, diagnostic evidence, and standard therapy.
    Denial Risk

    Non-Covered Unproven Indications

    Benlysta for uses outside active SLE or active lupus nephritis receiving standard therapy is considered experimental, investigational, or unproven and is not covered under this policy.

    • Anti-neutrophil cytoplasmic antibody-associated vasculitis / granulomatosis with polyangiitis
    • Antiphospholipid syndrome
    • Chronic obstructive pulmonary disease / emphysema
    • Cryoglobulinemia
    • Discoid lupus erythematosus
    • Graft-versus-host disease
    • Idiopathic CD4 lymphocytopenia
    • Idiopathic inflammatory myopathy
    • Immune thrombocytopenia (ITP), outside management of SLE
    • Immunoglobulin G4-related sclerosing disease, outside management of SLE
    • Myasthenia gravis
    • Neuromyelitis optica spectrum disorders
    • Relapsed chronic lymphocytic leukemia
    • Rheumatoid arthritis
    • Sjogren’s syndrome
    • Vasculitis, outside management of SLE
    Denial Risk

    Prohibited Concomitant Therapy

    Benlysta must not be used with prohibited concomitant therapies. Such combinations may result in denial even when other medical-necessity criteria are met.

    • For active SLE, do not use Benlysta with other biologic therapies or intravenous cyclophosphamide.
    • For active lupus nephritis, do not use Benlysta with other biologic therapies, including Actemra (tocilizumab), Enbrel (etanercept), Humira (adalimumab), or Stelara (ustekinumab).
    Denial Risk

    Insufficient Response or Stability Documentation

    Continuation may be denied when recent documentation does not demonstrate clinical improvement or disease stability after starting Benlysta.

    • Provide chart documentation dated within the last 6 months.
    • Document either sustained improvement/reduced flares or remission, low disease activity, or no new lupus disease activity compared with the prior assessment.
    Lupus and rheumatoid arthritis
    Autoantibody
    DefinitionAn antibody produced by the body's own immune system
    TargetAttacks the body's normal cells
    DistinctionAttacks normal cells rather than foreign antigens such as viruses and bacteria
    B Cells
    DefinitionCells in the body that help activate an immune response
    RoleParticipate in activation of the immune response
    ContextB cells are part of the body's immune system
    B-Lymphocyte Stimulator Protein (BLyS)
    Full nameB-lymphocyte stimulator protein (BLyS)
    DefinitionA molecule in the body
    RoleAids in the development of B cells
    Central Nervous System Lupus
    DefinitionA complication that can be seen in people with lupus
    Neurologic manifestationsMay involve seizures, cerebrovascular accidents (strokes), or delirium
    Other manifestationNerve pain
    Corticosteroid
    DefinitionA drug class
    Primary effectReduces inflammation
    Immune effectSuppresses the immune system
    Lupus Nephritis
    DefinitionInflammation of the kidney
    Associated conditionOccurs in people with lupus
    Clinical focusRepresents kidney involvement in lupus
    No Evidence Of
    DefinitionThe reviewer has not identified any records of the specified item or condition within the submitted materials or claims history
    Eligibility interpretationIn the absence of such evidence, the member is considered eligible
    Effect of evidence foundIf any evidence is present upon review, the member does not qualify